Table 4.

Additional therapy and follow-up.

	First diagnosis
	PXA (n = 51)	PXA-AF (n = 23)
Postoperative therapy, n (%)	—	—	—
Any type	17 (33.3%)	18 (78.3%)	—
Radiotherapy (RT) only	5 (9.8%)	3 (13.0%)	—
Radiosurgery (RS) only	1 (2.0%)	0	—
Chemotherapy +/− RT/RS	11 (21.6%)	14 (60.9%)	—
RT + RS	0	1 (4.3%)	—
Median follow-up, years (range)	11.2 (0.6–31.9)	4.0 (0.1–22.9)	—
Recurrence, n	21	11	—
Outcome, n	—	—	—
Alive	20	6	(0.1–25.4 years)*
Alive with disease	7	3	(0.8–20.0 years)*
Died	2	2	(4.0–20.5 years)*
Died of disease	6	8	(0.8–27.7 years)*
No evidence of disease	16	4	(0.6–31.9 years)*
5-year survival % (95% CI)	—	—	—
Recurrence-free	70.9% (58.0–83.8)	48.9% (26.5–71.3)	P = 0.092
Overall	90.4% (81.5–99.4)	57.1% (34.2–80.0)	P = 0.0003

^*Total available follow-up.

PXA = pleomorphic xanthoastrocytoma; PXA-AF = pleomorphic xanthoastrocytoma with anaplastic features.